TTrialPathMatch Me to Trials
← Back to trials
RecruitingAtrial Fibrillation

Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF

Eligible age

18–80 yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation in the treatment of subjects with symptomatic paroxysmal and persistent atrial fibrillation using the pulsed field ablation with the VARIPULSE™ catheter and the TRUPULSE™ generator.

Sponsor: Massachusetts General Hospital

You may qualify if…

  • ✓ Symptomatic paroxysmal and persistent AF with at least one AF episode electrocardiographically documented within 24 months prior to enrollment. Electrocardiographic documentation may include, but is not limited to ECG, Transtelephonic monitoring (TTM), Zio patch monitor, telemetry strip, or consumer devices
  • ✓ Age 18-80 years
  • ✓ Willing and capable of providing written consent
  • ✓ Able and willing to comply with all pre-, post- and follow-up testing and requirements.

You may not qualify if…

  • ✕ Previous surgical or catheter ablation for AF
  • ✕ Documented LA thrombus by imaging within 48 hours before procedure (CT, TEE, or intracardiac echocardiogram at the beginning of the procedure).
  • ✕ Uncontrolled heart failure or New York Heart Association (NYHA) Class IV
  • ✕ History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • ✕ Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study
  • ✕ Presence of implanted pacemaker or Implantable Cardioverter-Defibrillator (ICD) or other implanted metal cardiac device that may interfere with the PFA energy field
  • ✕ Women who are pregnant (as evidenced by pregnancy test if pre- menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the course of the clinical investigation
  • ✕ Life expectancy less than 12 months

Where it's recruiting

Arkansas

Jonesboro

New York

New York

Texas

Austin

Source: ClinicalTrials.gov · NCT06099730 · last updated 2026-07-27

Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wal · TrialPath